Heartflow (NASDAQ:HTFL) CFO Vikram Verghese Sells 3,587 Shares of Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 3,587 shares of Heartflow stock in a transaction on Monday, November 9th. The shares were sold at an average price of $53.15, for a total value of $190,649.05. Following the sale, the chief financial officer directly owned 149,587 shares of the company’s stock, valued at approximately $7,950,549.05. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Vikram Verghese also recently made the following trade(s):

• On Friday, September 18th, Vikram Verghese sold 16,766 shares of Heartflow stock. The stock was sold at an average price of $50.75, for a total transaction of $850,874.50.
• On Thursday, September 17th, Vikram Verghese sold 7,579 shares of Heartflow stock. The stock was sold at an average price of $50.11, for a total value of $379,783.69.
• On Tuesday, September 15th, Vikram Verghese sold 668 shares of Heartflow stock. The shares were sold at an average price of $50.01, for a total value of $33,406.68.
• On Monday, September 14th, Vikram Verghese sold 4,593 shares of Heartflow stock. The shares were sold at an average price of $50.24, for a total value of $230,752.32.
• On Friday, September 11th, Vikram Verghese sold 29,714 shares of Heartflow stock. The stock was sold at an average price of $50.06, for a total value of $1,487,482.84.
• On Tuesday, September 8th, Vikram Verghese sold 6,640 shares of Heartflow stock. The shares were sold at an average price of $50.03, for a total transaction of $332,199.20.
• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The shares were sold at an average price of $50.60, for a total value of $297,325.60.

Heartflow Trading Down 1.5%

Shares of NASDAQ:HTFL opened at $55.80 on Wednesday. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $60.56. The company has a market cap of $4.85 billion, a PE ratio of -30.49 and a beta of 2.50. The company’s 50 day moving average is $51.56 and its 200 day moving average is $34.87.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The business had revenue of $64.08 million during the quarter. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. Equities research analysts predict that Heartflow, Inc. will post -0.75 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HTFL. GAMMA Investing LLC boosted its position in Heartflow by 75.1% in the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock valued at $32,000 after buying an additional 275 shares during the period. Allworth Financial LP grew its holdings in shares of Heartflow by 116.4% during the third quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock worth $57,000 after purchasing an additional 616 shares during the last quarter. IFP Advisors Inc raised its position in Heartflow by 844.7% in the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company’s stock valued at $40,000 after purchasing an additional 718 shares during the last quarter. Strs Ohio grew its holdings in shares of Heartflow by 35.3% during the first quarter. Strs Ohio now owns 4,600 shares of the company’s stock worth $112,000 after buying an additional 1,200 shares during the last quarter. Finally, Integrated Wealth Concepts LLC acquired a new position in shares of Heartflow in the second quarter valued at approximately $53,000.

Analysts Set New Price Targets

HTFL has been the topic of several recent research reports. Morgan Stanley upped their price objective on Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a research report on Friday, August 14th. JPMorgan Chase & Co. upped their price target on Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a report on Friday, August 14th. Wells Fargo & Company increased their price target on Heartflow from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. UBS Group started coverage on Heartflow in a report on Wednesday, September 9th. They issued a “neutral” rating and a $55.00 price objective on the stock. Finally, Wall Street Zen lowered shares of Heartflow from a “buy” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Heartflow has an average rating of “Moderate Buy” and an average price target of $48.62.

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient’s coronary arteries and provide information that can support diagnosis and treatment planning. The company’s offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.